ABIONYX Pharma SA (0RAG.L)
| Previous close | 1.2440 |
| Open | 1.2500 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 1.2500 - 1.2500 |
| 52-week range | 1.0400 - 2.3200 |
| Volume | |
| Avg. volume | 850 |
| Market cap | 27.561M |
| Beta (5Y monthly) | -0.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1480 |
| Earnings date | 26 Sept 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
PARIS, July 03, 2024--Regulatory News: ABIONYX Pharma (Paris:ABNX):
Business WireABIONYX Carries out Successfully a Capital Increase With Cancellation of Preferential Subscription Rights for the Benefit of a Category of Persons Through the Issue of Shares With Warrants for an Amount of c.€3.4 Million
TOULOUSE, France & LAKELAND, Mich., July 01, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces the success of a capital increase with cancellation of preferential subscription rights for the benefit of a category of persons for an amount of close to €3.4 million through the issue of a maximum number
Business WireABIONYX Pharma announces unanimous approval of all resolutions put to the vote at its Combined General Meeting
TOULOUSE, France & LAKELAND, Mich., June 27, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces that all resolutions presented at its Combined General Meeting were unanimously approved.
